Analysis of the correlation between the expression of miR-655 and esophageal cancer prognosis

PENG CHANG, XIANGJUN WANG, YA ZHOU and YULONG HOU

Department of Thoracic and Cardiac Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P.R. China

Received October 17, 2016; Accepted March 6, 2017

DOI: 10.3892/ol.2017.6047

Abstract. The correlation between the expression level of microRNA (miR)-655 in esophageal cancer with proliferation, invasion and prognosis was investigated. Reverse transcription-quantitative polymerase chain reaction technique was used to detect the expression level of miR-655 in esophageal cancer cell lines KYSE410 and EC9706, tumor tissues and normal cancer-adjacent tissues of 63 cases of patients with esophageal squamous cell carcinoma (ESCC). The expression of miR-655 was upregulated in ESCC cells through the transfection of miR-655 mimics, and the influence of miR-655 on proliferation and invasion ability of ESCC cells was observed. Combined with the clinical data, the correlation between the expression of miR-655 and the prognosis of esophageal cancer was analyzed. The expression of miR-655 was downregulated in 2 ESCC cell lines and 73.02% of ESCC tissues. The results showed that the increased expression of miR-655 via transfection of mimics inhibited the proliferation and invasion ability of ESCC cells. Combined with clinical data analysis, it was found that the low-expression of miR-655 was related to poorer progression-free survival. In conclusion, the high-expression of miR-655 can inhibit the proliferation and invasion of ESCC, and plays a negative regulation role in the prognosis process of tumor patients. The targeted regulation of miR-655 can be used as a new treatment method of ESCC.

Introduction

Esophageal cancer is the world’s eighth most-common cancer, and the sixth cause of cancer death. Although the morbidity of Barrett glandular cancer is increasing rapidly in Western countries, esophageal squamous cell carcinoma (ESCC) still occupies a leading position in East Asia and China (1). ESCC is often diagnosed at later stage. Although there are a variety of treatment methods, such as surgery, chemotherapy and radiotherapy, the prognosis is not satisfactory (2).

MicroRNA (miRNA or miR) is a recently discovered, small (approximately 18-24 nucleotides in length) and non-coding single-stranded RNA that monitors and regulates gene expression (3). miRNA is involved in cellular physiological and pathological processes, including cell differentiation, proliferation, apoptosis and metabolism. Currently, increased number of studies have shown that miRNA can become a cancer biomarker and potential therapeutic target (4).

After editing and maturation, miRNA can combine with proteins into the RNA-induced silencing complex (RISC). In case RISC does not fully match with the target mRNA gene, it can cut off the miRNA translation and reduce the expression of target genes. When RISC fully matches with the target mRNA gene, it can cause the decomposition of miRNA. miRNA affects the target gene expression by cutting off or decomposing target mRNA to regulate a series of process, including cell differentiation and apoptosis (5,6).

The abnormal expression of miR-655 studied in this test has been confirmed in a variety of tumor tissues and tumor cells, including melanocytoma cells, lung adenocarcinoma cells and pancreatic cancer cells (7,8). Studies have proved that miR-655 can inhibit the epithelial-mesenchymal transition of tumor cells (9), but there is no report on the influence of miR-655 expression on the prognosis of ESCC at present.

This investigation used the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) technique to detect the expression of miR-655 in ESCC cell lines and removed tissues in clinical surgery, upregulated the expression of miR-655 in ESCC cells through mimic transfection to investigate the influence on ESCC cell proliferation and metastasis ability. The influence of miR-655 on the prognosis of ESCC was also studied combined with clinical data analysis.

Materials and methods

Materials. The following were obtained: RPMI-1640 medium, fetal calf serum (Gibco, Grand Island, NY, USA); RNA extraction kit (Invitrogen Life Technologies, Carlsbad, CA, USA); RT-qPCR kit (Takara Bio, Dalian, China); Transwell chamber (Corning Life Sciences, Oneonta, NY, USA); Lipofectamine® 2000, primer, miR-655 mimics (Invitrogen Life Technologies).
The human esophageal cancer cell lines, KYSE410 and EC9706, were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and normal esophageal epithelial cells, obtained via the isolation of the primary cells in 72 h culture, were from the normal cancer-adjacent tissues. A total of 63 cases of ESCC tissues and corresponding normal cancer-adjacent tissues used in the clinical research were from the tissue specimens after the esophageal cancer operation in Xuzhou Cancer Hospital (Xuzhou, China). All tissue specimens were diagnosed as squamous cell carcinoma by pathology analysis.

**Cell culture.** Two esophageal cancer cell lines, KYSE410 and EC9706, were cultured in RPMI-1640 culture solution (containing 10% fetal bovine serum, FBS) in 5% CO₂ and incubated at 37˚C, followed by passage once every 48-72 h. Cells in the exponential phase were taken for the experiment.

**Detection of miR‑655 expression in cells and specimens using RT‑qPCR method.** The total RNA was extracted from each group of cells and tissues using the TRizol method; 1 µg RNA was taken from the total RNA obtained in each group, and the reverse transcription was performed according to the operation method of the kit specifications. Then miR-655 primer was added, and the expression of miR-655 was detected using a two-step method for qPCR; U6 RNA was selected as the internal reference. The specific operation was in accordance with kit specifications. miR-655 primer sequence and U6 primer sequence are shown in Table 1; the reaction conditions were as follows: 50˚C for 2 min, 95˚C for 1 min, 95˚C for 5 sec, anneal and extension under 60˚C for 34 sec, 40 amplification cycles.

**Transfection of miR‑655 mimics.** Hsa-miR-655 mimics fragment and negative control (NC) sequences are shown in Table I. The transfection method was as follows: Cells were cultured using 6-well culture plate with the transfection of 2 µg per well; the transfection was performed in accordance with the specification of Lipofectamine® 2000; the experiment included the normal group, miR-NC group and hsa-miR-655 mimics group.

**Influence of miR‑655 mimics transfection on expression of miR‑655 and cell proliferation ability.** At 48 h after transfection according to the above method, the expression of miR-655 in cells in each group was detected according to the methods previously specified. The cells were transfected according to the above-mentioned method, digested with trypsin after 48 h, and prepared into the single-cell suspension using medium; then the suspension was added to the 96-well culture plate with 10⁴ cells per well. The experiment included the NC group and hsa-miR-655 mimics group. A total of 20 µl MTT solution (concentration of 5 µg/µl) was added at 24 h. Cells were incubated in the dark for 4 h, and 150 µl DMSO was added, followed by oscillation on the oscillator; the optical density value in 490 nm wavelength was measured, then the cell activity value was calculated.

**Influence of miR‑655 mimics transfection on ESCC cell invasion ability.** Transwell chamber was used, and the experiment included NC group and hsa-miR-655 mimics group; after the chamber was handled according to the operation method in the kit specifications, the transfected cells were prepared into the single-cell suspension containing 4x10⁵/ml cells; 100 µl cell suspension was added uniformly into the upper chamber, while 500 µl medium containing 30% FBS was added into the lower chamber. After 48 h, specimens were fixed and dyed, followed by microscopic observation and imaging analysis.

**Relationship between the expression of miR‑655 in ESCC and prognosis.** The inspection results in 1.3 were analyzed,
and the patients were divided into the miR-655 low-expression group and miR-655 high-expression group according to whether the decrease of miR-655 expression in ESCC tissues was more than doubled. There was no statistical significance in the age, gender, smoking history and other factors between the groups (P>0.05). According to the follow-up results, the progression-free survival (PFS) of the groups was calculated.

Statistical analysis. Data in this study are presented as mean ± standard deviation; in data processing, SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) was used for one-way ANOVA. P≤0.05 indicates the difference with statistical significance.

Results

Detection of miR-655 expression in cells and specimens using RT-qPCR method. Results showed that compared with normal cells, the expression of miR-655 was low in 2 ESCC cell lines, and the relative expression of miR-655 was 0.21±0.04 (KYSE410) and 0.357±0.02 (EC9706) (Fig. 1).

Among 63 ESCC specimens, the downregulated expression of miR-655 relative to the normal cancer-adjacent esophageal tissue was found in 46 patients (73.02%), and the upregulated expression of miR-655 was found in 17 patients (26.98%) (Fig. 2).

Influence of transfection of miR-655 mimics on miR-655 expression in ESCC cells. The influence of miR-655 mimics on miR-655 expression in ESCC cells was detected using RT-qPCR, and the results showed that miR-655 mimics increased the expression of miR-655 in KYSE410 cells 11.88-fold and in EC9706 cells 9.05-fold (Fig. 3).

Influence of transfection of miR-655 mimics on ESCC cell proliferation ability. The influence of miR-655 on ESCC cell proliferation was detected using MTT method. Results showed that after the transfection of miR-655 mimics, the proliferation of KYSE410 and EC9706 was inhibited 47.33 and 54.92%, respectively, and the differences had statistical significance (P<0.01; Table II).

Influence of transfection of miR-655 mimics on ESCC cell invasion ability. The influence of miR-655 on ESCC cell invasion was detected through Transwell cell invasion assay, and the results showed that after KYSE410 was transfected with miR-655 mimics, the number of cells crossing it was 215±7 cells/HP in NC group and 66±5 cells/HP in miR-655 transfection group, and the differences had statistical significance (P<0.01); after EC9706 was transfected with miR-655 mimics, the number of cells crossing it was 191±6 cells/HP in NC group and only 72±7 cells/HP in miR-655 transfection group, and the differences had statistical significance (P<0.01). The results showed that miR-655 effectively inhibited the invasion ability of ESCC cells (Fig. 4).

Relationship between miR-655 expression in ESCC and prognosis. Kaplan-Meier analysis suggested that the mean
PFS was 17.20±1.38 months in the miR-31 low-expression group and 26.50±1.23 months in the miR-655 high-expression group, and the differences had statistical significance (Fig. 5).

Discussion

According to literature reports, both morbidity and mortality of esophageal cancer are very high in China, and ranks as fourth in malignant tumors, posing a great threat to people's health and family life (10,11).

Studies have found that miRNA can regulate the expression of tumor-related genes with the characteristics of oncogenes or cancer suppressor genes. Studied have also found that miRNA has a significant role in tumor inhibition during the process of tumor generation (12). Some reports also show that the expression of miR-21 is high in most tumors and it acts as an oncogene (13). A large amount of data have proved that the expression of miRNA is abnormal in a variety of tumors and this is correlated to the diagnosis and prognosis of the tumor (14).

miRNA has high tissue specificity, which can be used as both tumor suppressor gene and oncogene (15,16). miRNA has a variety of biological characteristics, which can act as an index of early tumor diagnosis and a predictive marker of prognosis (5,17). miRNA is involved in tumor generation and development. The expression of miRNA in tumor cells and normal tissues is significantly different (1,18,19).

This study found that the expression of miR-655 in ESCC cell lines was decreased significantly compared with that in normal cells. Among 63 ESCC specimens, the downregulated expression of miR-655 relative to the normal cancer-adjacent esophageal tissue was found in 73.02% of specimens, and the upregulated expression of miR-655 was found in 26.98% of specimens. In order to study the influence of miR-655 on ESCC cells, an experimental study was further performed and the expression of miR-655 in cells was increased through the transfection. The results showed that the high-expression of miR-655 could inhibit the proliferation and invasion abiliy of ESCC cells. These results suggested that miR-655 has the effect of inhibiting tumor in ESCC cells. In addition, the clinical data showed that the median survival time of patients with high-expression of miR-655 was longer than those with low-expression of miR-655. Therefore, transferring miR-655 into tumor cells can potentially prevent tumor generation to optimize patient prognosis. miR-655 may be a kind of new biomarker to diagnose and predict the prognosis of ESCC.

References

1. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budha A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res 15: 6192-6200, 2009.

2. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL and Madhusudan S: Biomarkers of response to therapy in oesophageo-gastric cancer. Gut 58: 127-143, 2009.

3. Farazi TA, Spitzer JJ, Morozov P and Tuschi T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.

4. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamini H, Shabes N, Tabak S, Levy A, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008.

5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.

6. Hobert O: Gene regulation by transcription factors and microRNAs. Science 319: 1785-1786, 2008.

7. Wang Y, Zang W, Du Y, Ma Y, Li M, Li P, Chen X, Wang T, Dong Z and Zhao G: Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. J Transl Med 11: 301, 2013.

8. Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K and Gemma A: MiR-134/487b/655 cluster regulates epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 13: 444-453, 2014.

9. Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J and Kozaki K: miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBFR2. PLoS One 8: e62757, 2013.

10. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.

11. Chen W, Zheng R, Zeng H, Zhang S and He J: Annual report on status of cancer in China, 2011. Chin J Cancer Res 27: 2-12, 2015.

12. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 in acute lymphoid leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.

13. Pan X, Wang ZX and Wang R: MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol Ther 10: 1224-1232, 2010.

14. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.

15. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S and Cole CN: Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620, 2007.

16. Medina PP, Nolde M and Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90, 2010.

17. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Müller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1170, 2010.

18. Davis E, Caïment F, Tordoir X, Cavaillé J, Ferguson-Smith A, Cockett N, Georges M and Charlier C: RNAi-mediated allelic trans-interaction at the imprinted Rtl1 locus. Curr Biol 15: 743-749, 2005.

19. Castilla MA, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García MA, Pratt J, Matías-Guiu X, Cano A, Oliva E, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinomas. J Pathol 223: 72-80, 2011.